ロード中...
Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin
BACKGROUND: Kidney transplant recipients are given induction therapy to rapidly reduce the immune response and prevent rejection. Guidelines recommend that an interleukin-2 receptor antibody (basiliximab) be the first-line agent and that a lymphocyte-depleting agent (antithymocyte globulin [ATG]) be...
保存先:
| 出版年: | Can J Kidney Health Dis |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7573718/ https://ncbi.nlm.nih.gov/pubmed/33117549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2054358120964061 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|